Form 4 for CAI Caris Life Sciences, Inc.
Accepted 2025-06-23 00:00:00 ET · period of report 2025-03-03 · accession 0001104659-25-061810 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-23 | 2025-06-20 | CAI | Denton John Russel | See Remarks | P - Purchase | $21.00 | +7,500 | 123.6K | +6% | +$157.5K |
| D | 2025-06-23 | 2025-03-03 | CAI | Denton John Russel | See Remarks | D - Sale to Iss | $18.60 | -238.2K | 16.8K | -93% | -$4.43M |
| D | 2025-06-23 | 2025-06-18 | CAI | Denton John Russel | See Remarks | A - Grant | $0.00 | +99.3K | 116.1K | +592% | $0 |
| D | 2025-06-23 | 2025-03-03 | CAI | Denton John Russel | See Remarks | A - Grant | $0.00 | +255.0K | 255.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | P | A | 7,500 | $21.00 | 123,591 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-03 | D | D | 238,230 | $18.60 | 16,770 | D | — | — | (F1) Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note. (F2) These securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025. |
| 3 | Common | Common Stock | 2025-06-18 | A | A | 99,321 | $0.00 | 116,091 | D | — | — | (F3) Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. |
| 4 | Derivative | Stock Option | 2025-03-03 | A | A | 255,000 | $0.00 | 255,000 | D | $18.60 · — to 2035-03-03 | 255,000 Common Stock | (F4) The stock option vested 60% at grant and will vest 20% on September 1, 2025 and 20% on September 1, 2026. These securities were previously reported on the Reporting Person's Form 3. |